NCT07254884

Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring

Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring Treatment to Lift the Eyebrow, Submental Lax Tissue and Address Advanced Signs of Facial Aging

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: FA Corporation · Industry
• Sex: All
• Age: 45 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this clinical trial is to evaluate the safety and effectiveness of the 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical) for non-invasive dermatological aesthetic treatment of three facial regions: eyebrow lift (Region 1), submental tissue lift (Region 2), and improvement of rhytids and skin laxity in the cheeks, midface, and jawline (Region 3).

Conditions

• Rhytids
• Skin Laxity

Interventions

Type	Name	Description
DEVICE	2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical)	Enrolled subjects will receive a series of two with an optional third 2,910 nm Fiber Laser treatments using fractional ablative resurfacing modes, laser-coring and full ablation addressing the full face and upper neck.

Timeline

• Start date: 2025-11-01
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2025-11-28
• Last updated: 2025-11-28